Navigation Links
DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs
Date:8/4/2011

http://www.durect.com/">www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT CorporationDURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR®, ELADUR®, and DURIN® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement The statements in this press release regarding Pfizer's on-going review and interactions with FDA regarding approval of the REMOXY NDA and the potential of resolving all outstanding regulatory concerns regarding REMOXY, anticipated completion of enrollment of BESST and receipt of top-line data for POSIDUR, future development activities and possible licensing transactions relating to TRANSDUR-Sufentanil, future development activities regarding ELADUR, anticipated optimization of a formulation for O
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. DURECT Corporation Invites You to Join its Second Quarter 2011 Earnings Conference Call
2. DURECT to Present at the Jefferies Healthcare Conference
3. DURECT Announces Resignation of Chief Medical Officer
4. DURECT to Present at the UBS Global Specialty Pharmaceuticals Conference
5. DURECT Announces ELADUR® (TRANSDUR®-Bupivacaine) Phase II Study Results in Chronic Low Back Pain
6. DURECT to Present at Cowen and Company Health Care Conference
7. DURECT Corporation Invites You to Join its Fourth Quarter 2010 Earnings Conference Call
8. DURECT Reports Data From European Phase IIb Shoulder Study of POSIDUR™ (SABER™-Bupivacaine) and Amendment of the Nycomed Agreement
9. DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product
10. DURECT to Present at the BIO CEO & Investor Conference
11. DURECT to Present at the Credit Suisse 2010 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... addition of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses ... in the United States . Reimbursement ... studied. Thorough product analyses for more than 73 SMBG ...
(Date:12/22/2014)... 2014  ConvaTec, a privately-held medical products and technologies ... Interim Chief Executive Officer of the company, effective December ... Berger .  "The Board of Directors of ConvaTec thanks ... the past three years," said Magnus Lundberg , ... confident that the company is well positioned for the ...
(Date:12/22/2014)... Mass , Dec. 22, 2014 /PRNewswire/ -- RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today issued the following open letter ... Cauwenbergh , Dr. Med. Sc. Dear ... days a number of inaccurate statements posted on ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... (NYSE: DHR ) announced that Executive Vice President ... at the Goldman Sachs Global Industrials Conference in New York, ... The company also announced that President and Chief Executive Officer, ... W. Baird Industrial Conference in Chicago, Illinois on Tuesday, November ...
... (Nasdaq: ITMN ) today announced results from ... September 30, 2010.  InterMune also highlighted its recent clinical ... financial guidance for 2010.   Dan Welch, ... "Earlier this month we announced the sale of our ...
Cached Medicine Technology:InterMune Reports Third Quarter 2010 Financial Results 2InterMune Reports Third Quarter 2010 Financial Results 3InterMune Reports Third Quarter 2010 Financial Results 4InterMune Reports Third Quarter 2010 Financial Results 5InterMune Reports Third Quarter 2010 Financial Results 6InterMune Reports Third Quarter 2010 Financial Results 7InterMune Reports Third Quarter 2010 Financial Results 8
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a comprehensive high-tech ... marketing of a series of induction heating equipment. Today, ... of induction brazing equipments . , According to ... refers to the joining of two or more ... manager says that there are fundamental differences in the ...
(Date:12/25/2014)... 26, 2014 The microscopy market ... 7.2% to reach $5,756.0 million by 2019. Optical ... market. The electron microscopes product segment is expected ... period. , Rising focus on nanotechnology, technological advancements, ... the microscopy market. , Get Full Copy of ...
(Date:12/25/2014)... The click strand woven bamboo flooring ... the business announces a click strand woven bamboo ... 2015. , Click strand woven bamboo flooring replicates ... well-known brand in the bamboo industry. It promises ... bamboo flooring supplier. , “We are happy to ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. TS-1 is an anti-cancer drug which is ... orally and is also used for treating gastric cancer ... and otastat potassium. The drug was first approved in ...
(Date:12/25/2014)... December 26, 2014 “Every three months the ... changes. A-line sweetheart evening dress will be one of the ... manager of Yunx.co.uk says. Today, the company releases 26 A-line ... up to 80% off. , “We are trying our ... style with our latest designs. Along with affordable prices, we ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... made available on the World Wide Web - a database ... the body. // ,The researchers had earlier identified flaws ... of cells called cilia as such a common link. They ... links associated with the tiny, hair-like cilia and implications for ...
... and the Raigmore in Inverness do not maintain hygiene standards, ... ,The study categorized hospitals by traffic light with ... set standards, amber for hospitals in the 70% and 90% ... the rate was 84.1%, while Raigmore scored 83.1% and the ...
... Pune declared Tuesday there is no Hantavirus in the flood ... Gujarat.// ,Additional director of NIV, M.S. Chaddha said: ... even a single sample contained Hantavirus." ,The medical ... two persons had died last week. Dipak Tarsariya (24) and ...
... exposed to lead on the job are 50 percent more ... not// exposed. The study author Edwin van Wijngaarden, ... risk factors such as lead must be explored. The ... a lead-cancer link, was based on the information from the ...
... held recently in Toronto. Around 24,000 scientists and activists ... that development of poor countries relies on the programs ... in the rich countries. ,Around 5 years back, ... people in poor countries who were infected with HIV ...
... doctors were stranded for days at the Charity Hospital, when ... of the storm, Charles Gibson reports from that hospital. ... might think you're in a warehouse or some kind of ... ,Charity Hospital served the poor and uninsured people ...
Cached Medicine News:Health News:John Hopkins Develops An Online Tool To Help In Research Of Certain Rare Diseases 2Health News:John Hopkins Develops An Online Tool To Help In Research Of Certain Rare Diseases 3Health News:People Exposed To Lead Likely To Die From Brain Cancer 2Health News:Fighting AIDS – a joint venture of the rich and the poor 2
Straight crisscross serrated tips. Flat handle with holes and polished finish....
0.5 mm, 1 x 2 teeth set at 45 degrees. Serrated handle with polished finish....
Serrated handle with 7 mm tying platform and polished finish. Teeth: 0.25 mm, 2 x 2 set at 45 degrees....
1 x 2 teeth and 5.5 mm tying platform. Round knurled handle with polished finish. Teeth: 0.3 mm....
Medicine Products: